Compare · CVRX vs WST
CVRX vs WST
Side-by-side comparison of CVRx Inc. (CVRX) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVRX and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.31B, about 180.0x CVRX ($129.5M).
- Over the past year, CVRX is down 41.8% and WST is up 28.7% - WST leads by 70.5 points.
- WST has been more active in the news (6 items in the past 4 weeks vs 1 for CVRX).
- WST has more recent analyst coverage (18 ratings vs 13 for CVRX).
- Company
- CVRx Inc.
- West Pharmaceutical Services Inc.
- Price
- $4.87+1.88%
- $331.17+0.86%
- Market cap
- $129.5M
- $23.31B
- 1M return
- -7.50%
- -4.38%
- 1Y return
- -41.82%
- +28.69%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 6
- Recent ratings
- 13
- 18
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest CVRX
- CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
- CVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- CVRx Announces Chief Financial Officer Transition
- Director Nielsen Kirk G. was granted 8,720 shares (SEC Form 4)
- Director Jain Mudit K. was granted 8,720 shares, increasing direct ownership by 154% to 14,370 units (SEC Form 4)
- Director Slattery Joseph P was granted 8,720 shares, increasing direct ownership by 28% to 39,365 units (SEC Form 4)
- Director Hill, Mitch C. was granted 8,720 shares (SEC Form 4)
- Director Ballinger Kevin J. was granted 8,720 shares (SEC Form 4)
- Director Shadan Martha was granted 8,720 shares (SEC Form 4)
- Director Dale Michael D was granted 29,005 shares (SEC Form 4)
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target